Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 17;65(9):e0264620.
doi: 10.1128/AAC.02646-20. Epub 2021 Aug 17.

In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii

Jacinda C Abdul-Mutakabbir  1 , Logan Nguyen  1 , Philip T Maassen  1 , Kyle C Stamper  1 , Razieh Kebriaei  1 , Keith S Kaye  2 , Mariana Castanheira  3 , Michael J Rybak  1   4   5
Affiliations

In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii

Jacinda C Abdul-Mutakabbir et al. Antimicrob Agents Chemother. .

Abstract

Cefiderocol (CFDC), a novel siderophore cephalosporin, demonstrates strong activity against multidrug-resistant (MDR) Acinetobacter baumannii. Limited studies have evaluated CFDC alone and in combination with other Gram-negative antibiotics against MDR A. baumannii isolates. Susceptibility testing revealed lower CFDC MIC values (87% of MICs ≤ 4mg/liter) than the comparator Gram-negative agents. Six isolates, with elevated CFDC MICs (16 to 32 mg/liter) were selected for further experiments. Time-kill analyses presented with synergistic activity and beta-lactamase inhibitors increased CFDC susceptibility in each of the isolates.

Keywords: A. baumannii; Gram-negative; cefiderocol; multidrug-resistant infection.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Six isolates with elevated CFDC MICs tested alone and in combination with other Gram-negative agents in TKA.
FIG 1
FIG 1
Six isolates with elevated CFDC MICs tested alone and in combination with other Gram-negative agents in TKA.
See this image and copyright information in PMC

References

    1. Doi Y, Bonomo RA, Hooper DC, Kaye KS, Johnson JR, Clancy CJ, Thaden JT, Stryjewski ME, van Duin D, Gram-Negative Committee of the Antibacterial Resistance Leadership Group (ARLG). 2017. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis 64:S30–S35. 10.1093/cid/ciw829. - DOI - PMC - PubMed
    1. Wenzler E, Goff DA, Humphries R, Goldstein EJC. 2017. Anticipating the unpredictable: a review of antimicrobial stewardship and Acinetobacter infections. Infect Dis Ther 6:149–172. 10.1007/s40121-017-0149-y. - DOI - PMC - PubMed
    1. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA. 2012. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis 73:267–270. 10.1016/j.diagmicrobio.2012.04.002. - DOI - PubMed
    1. McCann E, Srinivasan A, DeRyke CA, Ye G, DePestel DD, Murray J, Gupta V. 2018. Carbapenem-nonsusceptible Gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study. Open Forum Infect Dis 5:ofy241. 10.1093/ofid/ofy241. - DOI - PMC - PubMed
    1. Pogue JM, Mann T, Barber KE, Kaye KS. 2013. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther 11:383–393. 10.1586/eri.13.14. - DOI - PubMed

MeSH terms

LinkOut - more resources